Investigators assessed the diagnostic performance of AST to Platelet Ratio Index and Fibrosis-4 scores compared with transient elastography evaluation of liver stiffness to detect significant fibrosis or cirrhosis.
Researchers suggest that novel biologicals should be explored as a treatment alternative to hepatitis vaccination for patients who are being treated with immunosuppressive drugs.
From a nationwide Swedish registry, researchers found data that showed in patients with hepatitis B or C virus infection, the long-term hepatocellular carcinoma risk was lower in patients who were treated with lipophilic statins.
Investigators found data that showed patients with hepatitis C virus infection who had a sustained viral response to treatment with interferon had less incidence of extrahepatic manifestations.
Drug interactions between antiretroviral therapy (ART) and direct-acting antivirals (DAAs) pose a clinical challenge in patients with HIV/hepatitis C virus (HCV) coinfection.
In this prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and with lower risk for progression to advanced fibrosis.
Findings of the analysis also revealed that some evidence indicates that liraglutide improves liver fat, liver function, and HbA1c, and may aid in NASH resolution and weight reduction.
Patients with hepatitis C virus (HCV) and cirrhosis can develop high-risk gastroesophageal varices (GEV) after sustained virological response (SVR). Surveillance is especially recommended in those with GEV before antiviral treatment.
Dried blood spot specimens could be a reliable alternative testing specimen, which may increase hepatitis B and C diagnostic opportunities for rural, remote, and hard to reach regions.
Clinical trials evaluating seladelpar for the treatment of non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) have been halted after atypical histological findings were observed in a phase 2b study in NASH patients.
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for obeticholic acid (Intercept) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).
